August 20, 2014 9:34 PM ET

Pharmaceuticals

Company Overview of Constellation Pharmaceuticals, Inc.

Executive Profile

Mark A. Goldsmith M.D., Ph.D.

AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 5 different industries.

See Board Relationships
52--

Background

Dr. Mark A. Goldsmith, M.D., Ph.D., is a Partner at Third Rock Ventures, LLC. Dr. Goldsmith serves as an Interim Chief Executive Officer of Nurix, Inc. Dr. Goldsmith served as the Interim Chief Executive Officer of Global Blood Therapeutics, Inc until June 2014. Previously, Dr. Goldsmith was a Venture Partner. Dr. Goldsmith served as an Assistant Director of the Gladstone Institute of Virology and Immunology of J. David Gladstone Institutes. Prior to joining Third Rock, ...

Corporate Headquarters

215 First Street
Cambridge, Massachusetts 02142

United States

Phone: 617-714-0555
Fax: 617-661-5382

Board Members Memberships

Former Chairman, Chief Executive Officer, and President
Executive Chairman
Director
Director

Education

BA
Princeton University
Post-Doctoral Training
Harvard Medical School
PhD
University of California-San Francisco
MD
University of California-San Francisco

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Constellation Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.